The expression of costimulatory molecules such as CD70 or CD80 by gene -modified tumor cells has been shown to enhance the antitumor immune response based mainly on T lymphocytes. However, most human tumors show defects of major histocompatibility complex ( MHC ) expression, preventing them from being recognized by MHC -restricted T cells. To investigate if coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumor responses in low and high MHCexpressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS / A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene -modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines, TS / A and B16.F10, resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumor response induced by combining CD70 and CD80. However, rejection of the CD70 / CD80 -transfected tumor cells appeared more effective in the MHC class I high TS / A model, leading to a protection against parental tumor cells. B16.F10 and TS / A transfectants were then tested with fibroblasts genetically modified to secrete interleukin -12 ( IL -12 ) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL -12 and CD70 / CD80 gene -modified cells generated an antitumor response to established tumors leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immuno -modulatory molecules could provide additional strategies for cancer immuno -gene therapy, even for MHC expression ± deficient tumors. Cancer Gene Therapy ( 2000 ) 7, 1543 ± 1556
V arious studies have examined the mechanisms by which tumors evade the immune response. These mechanisms included, among others, the lack of tumor antigen ( Ag ) expression, down -regulation of surface major histocompatibility complex (MHC ) molecules or loss of peptide processing components, and production of suppressor factors or lack of costimulatory molecules. 1 Therefore, one of several strategies to increase tumor immunogenicity and enhance antitumor T-cell responses is to genetically modify tumor cells to express costimulatory molecules. 2 Indeed, Tlymphocyte activation requires two signals, an Ag -specific signal delivered through the T-cell receptor ( TCR ) and a second non-Ag specific or``costimulatory signal'' delivered by accessory receptors following their engagement with ligands expressed mostly by Ag -presenting cells (APCs ). 3, 4 In the absence of such signals, TCR interaction with Ag / MHC complex may result in unresponsiveness, anergy or programmed cell death. 5 ± 7 One of the best characterized costimulatory molecules is CD80, which belongs to the immunoglobulin family. 8 Engaging CD28 through its ligand CD80, simultaneously with TCR activation leads to the generation of T-cell proliferative and cytokine production responses.
7,9 ± 11 The transfection of CD80 into murine tumor cells increases antitumor T-cell immunity and leads to tumor regression in many models. 12 ± 15 However, the intrinsic immunogenicity of the tumor is critical for the outcome of the immune antitumor response mediated by CD80. 16 These results suggest that certain tumors may be lacking the additional cell surface molecules needed for complete Tcell activation such as MHC molecules and /or other cell surface costimulators. To improve an immune antitumor response mediated by efficient costimulatory signals, we combined CD80 transfection with transfection of another costimulatory molecule, CD70.
17 CD70 belongs to the tumor necrosis factor family 18, 19 and is known through its interaction with CD27 to regulate the size and function of Ag -primed lymphocyte populations. 20 ± 22 The transfection of CD70 in some immunogenic murine tumor cells have been shown to induce tumor regression and to enhance an antitumor immunity T-cell mediated. 17, 23, 24 Furthermore, cotransfection of both CD70 and CD80 into the poorly immunogenic MCA 207 tumor cells in the presence of interleukin -12 ( IL-12) has been shown to enhance a protective antitumor immunity against parental tumor growth in a vaccination model. 17 Looking toward the treatment of human cancer, the present study aimed to establish a potent immunotherapy for tumors that lack apparent immunogenicity, and more specifically for such MHC -deficient expression tumor cells. Indeed, detailed studies of MHC gene products revealed that defects in MHC class I expression are widespread among human tumors. We then wanted to investigate whether costimulatory signals through CD80 / CD28 and CD70 / CD27 could cooperate to improve an efficient antitumor response even with a low MHC class I expression on tumor cells. CD70 and CD80 were then transfected into two low immunogenic tumor cell lines, the B16.F10 melanoma and the TS /A mammary adenocarcinoma murine cell lines expressing, respectively, low and high levels of MHC class I molecules. CD70 and CD80 coexpression resulted in an increased capacity of gene -modified tumor cells to costimulate in vitro optimally activated lymphoid cells. In both models, CD70 /CD80 -transfected tumor cells resulted in the T-cell ±mediated partial regression of subcutaneous (s.c. ) tumors in mice. However, rejection of the CD70 / CD80 tumor cells appeared more effective in the MHC class I high TS / A model than in the B16.F10 model. We further studied the effect of IL -12 on these CD70 /CD80 -mediated antitumor responses. Indeed, IL-12 is a good candidate for treatment against MHC class I ±deficient expression tumors as it is able to activate both Th1 responses and MHC nonrestricted NK effectors.
25 CD70 /CD80 tumor cells, when associated with IL -12 ±transfected fibroblasts generated antitumor response to established parental tumors in the TS / A as well as in the B16.F10 tumor model. These findings demonstrate that the combination of costimulatory molecules could improve cytokine-based immunotherapy, even for MHC expression ±deficient human tumors.
MATERIALS AND METHODS

Antibodies and reagents
Monoclonal antibodies ( mAbs ) used to phenotype tumorinfiltrating leukocytes by immunochemistry: rat anti -mouse CD4 mAb (GK1.5 ) and rat anti -mouse CD8 mAb (53 ± 6.1 ) were purchased from Southern Biotechnology ( Birmingham, UK ) . Biotinylated rabbit anti -rat IgG and streptavidine conjugated to horseradish peroxidase were purchased from Dako (Glostrup, Denmark Phenotypic analysis of MHC expression by flow cytometry was performed with supernatants kindly provided by J. E. Gairin ( Toulouse, France ). These supernatants were from the anti ± H -2D b and H -2L d hybridoma cell line (28-14-8S) , the anti ± H -2K b hybridoma cell line (SF1 ) and the anti ±H -2K b hybridoma cell line ( Y3 ) from ATCC. The second staining step was performed using FITC -conjugated sheep anti -mouse IgG purchased from Sigma ( St. Louis, MO ). The mAbs used to control CD70 and CD80 cell surface expression are fluorescein isothiocyanate (FITC ) -conjugated mouse anti -human CD80 mAb, mouse anti -human CD70 mAb purchased from Pharmingen (Hamburg, Germany ) and phycoerythrin (PE ) -conjugated sheep anti -mouse IgG purchased from Sigma. We used anti -mouse CD3" ( Pharmingen ) to perform in vitro lymphocyte stimulation.
Retroviral constructs
The construction and characterization of the polycistronic TFG murine IL-12 retroviral vector ( TFGmIL -12) coding for both p35 and p40 murine IL -12 subunits, of the dicistronic DFG human CD80 ( DFGhCD80 ) and of the DFG human CD70 (DFGhCD70 ) retroviral vectors have been previously described. 17, 28, 29 These MFG -based retroviral vectors express such molecules along with a neo R or zeo R selectable marker. The control vector consisted of the MFG retroviral vector with an internal ribosome entry site ( IRES ) neo R sequence.
Cell lines
TS /A is a tumor cell line established by P. Nanni ( Bologna, Italy) derived from a spontaneous mammary adenocarcinoma of the BALB /c strain 30 and kindly provided by P. Lollini (Bologna, Italy ). B16.F10 is a variant of B16, a melanoma cell line of C57BL /6 origin kindly provided by J. Galea-Lauri (London, UK ) . We obtained from Lea Eisenbach (Weizmann Institute, Israel ) MHC class I positive B16F10 cells named B16K1. 31 The syngeneic fibroblasts from B6 mice ( MC57 ) and from BALB /c mice ( balbc ) were kindly provided by J. E. Gairin ( Toulouse, France) . IL -12 ±producing MC57 ( MC57 IL -12) or balbc cells ( balbc IL -12 ) were obtained by transfection with the TFG mIL -12 retroviral vector using LIPOFECTAMINE PLUS 2 as described by the supplier (Gibco-BRL, Cergy Pontoise, France ). Following selection with G418 ( Gibco -BRL ) , transfected fibroblasts produced up to 1.5 ng mIL -12 /10 6 cells / 48 hours, as determined routinely by a quantitative``sandwich'' ELISA enzyme immunoassay using a mIL -12 ELISA kit ( Genzyme, Cambridge, MA ) according to standard protocols. The MFGneo ( mock ) , DFGhCD70 (CD70 ) and /or DFGhCD80 (CD80 ) vectors or TFG CD70/CD80 were transfected into B16.F10 and TS / A cells using LIPOFECTAMINE PLUS 2 . The stably transfected cells, B16.F10 mock, B16.F10 CD70, B16.F10 CD80, B16.F10 CD70 / CD80, B16K1 CD70/CD80 TS /A mock, TS /A CD70, TS / A CD80, TS / A CD70 /CD80 were selected using G418 ( 1 mg /mL ) and /or Zeocyne ( 0.1 mg / mL ) ( Cayla, Toulouse, France ) depending on the plasmids and the resistant cells used in subsequent experiments.
These cell lines were cultured in RPMI 1640 medium with 2 mM L -glutamine (Gibco -BRL ) except the balbc cell line, which was cultured in Dulbecco's modified Eagle's medium ( Gibco -BRL ), supplemented with 2 mM glutamine and 10% fetal calf serum ( FCS ) (Life Technologies, CergyPontoise, France ). All cell lines were tested periodically for mycoplasma using a DNA hybridization probe (Stratagene, La Jolla, CA ) or the``Molli'' technique. 32 
Flow cytometric analysis
Staining of costimulatory molecule transfected cells was performed with FITC -conjugated anti -human CD80 ( 0.1 g/ mL ) and/ or anti -human CD70 ( 0.1 g/mL ). Cells were trypsinized, washed twice with phosphate -buffered saline ( PBS ) 2% FCS, and incubated for 30 minutes at 48C with specific mAbs. Cells were washed twice with PBS 2% FCS and incubated for an additional 30 minutes at 48C with the second mAb, PE -conjugated anti -mouse IgG ( 1/ 200) for CD70 analysis. After two further washings, stained cells were fixed in PBS 1% paraformaldehyde and analyzed on a Becton Dickinson FACscan interfaced to a Hewlett Packard computer (Mountain View, CA ). Stain specificity was confirmed by analysis of MFG neo mock transfected cells. For MHC expression analysis, the first incubation step was performed with 1 mL of undiluted supernatant from the appropriate hybridoma cell line followed by FITC -conjugated sheep anti -mouse IgG (1 /200 ) as described previously. TS /A cells stained with anti -K d and B16.F10 stained with anti -K b followed by FITC -conjugated sheep anti -mouse IgG were used as controls. Data were collected on 10,000 cells.
Lymphoid cell preparation
Inguinal and axillary lymph nodes were harvested from naive C57BL /6 or BALB /c mice, pooled, and minced. Single -cell suspensions were prepared by filtration through sterile nylon mesh ( Poly Labo, Strasbourg, France ) and residual red blood cells were removed with erythrocyte lysis buffer (Tris ±HCl 0.01 M, NH 4 Cl 0.83%, pH 7.4) . The cells were brought to a concentration of 10 6 cells/mL in RPMI 1640 medium supplemented with 10% heat -inactivated FCS, 5Â10
À 5 M -mercaptoethanol, 10 mM Hepes buffer, 0.1 mM nonessential amino acids, and nonessential vitamins ( Sigma, Saint Quentin Fallavier, France ), and incubated at 378C in a 5% CO 2 humidified atmosphere until used.
Proliferation assays
Lymphoid cells were stimulated in vitro by incubating 10 [6 - 3 H ] thymidine ( Amersham Life Science, Buckinghamshire, UK ) . Cells were assayed for thymidine incorporation using a -counter. The results from five separate wells were averaged and are reported as mean standard deviation ( SD ). Statistical analysis for comparison between stimulations was conducted with a Student's t test.
Assays of interferon -gamma ( IFN -) content
In experiments for IFN -assays, lymphoid cells were cultured for 3 days with irradiated transfected tumor cells in a final volume of 200 L in 96 -well round -bottomed plates as described for the proliferation assay but without IL -2. After 72 hours, 100 L of supernatant was harvested and assayed for murine IFN -content by a quantitative``sandwich'' ELISA enzyme immunoassay using an mIFN -ELISA kit ( Pharmingen ) according to the standard protocol. In these assays, the detection limit for IFN -using ELISA was between 50 and 100 pg /mL. The data represent means SD of triplicate cultures from a single experiment representative of one additional experiment. Statistical analysis for comparison between stimulations was conducted with a Student's t test.
Mice
Female BALB /c, NMRI nu /nu, C57BL /6, and C57BL /6 nu /nu mice were purchased from the CERJ JANVIER (Le Genest Saint -Isle, France ) . We obtained from Yost Van Meerwijk (Inserm U395 Toulouse, France ) 2 -microglo- Figure 2 . Analysis of CD70, CD80, CD70 / CD80 expression by the B16.F10 -, the TS / A -, and the B16K1 -transfected tumor cells. Parental or transfected B16.F10 and TS / A cells are stained for the surface expression of CD70 alone ( A ) , CD80 alone ( B ) , or CD70 and CD80 ( C ) . B16K1 are stained for the surface expression of both CD70 and CD80 ( D ) . This has been performed using FITC -labeled anti -human CD80 mAb alone and / or anti -human CD70 mAb followed by PE -labeled anti -mouse IgG. CD70 or / and CD80 expression are analyzed by flow cytometry. Tumor cell line B16K1 were stained for the surface expression of MHC class I molecules using specific mAb as described in 6 gamma-ray ± irradiated CD70 /CD80 tumor cells ( 100 Gy ) and/ or 10 6 irradiated mIL -12 ± transfected syngeneic fibroblasts ( 100 Gy ) . Therapeutic injections began on day 4 and were repeated every 3 days for the B16.F10 model or every 4 days for the TS / A model, depending on the parental tumor growth rate. The results are expressed as mean size (mm 2 ) of tumors from groups of five mice each SD. The significance of differences in tumor growth rate was determined by an ANOVA test. We used an analysis of variance for repeated measures ( time ) with a grouping factor ( H ).
Immunochemistry
On days 4, 6, and 12 after TS /A tumor challenge or on days 4, 7, and 14 after B16.F10 tumor challenge, or on day 20 for therapy experiments, the mice were killed and the tumors in each group were surgically excised. Tumor fragments were embedded in Cryomatrix ( Life Science International, Cheshire, UK ), snap frozen in liquid nitrogen, and stored at À 808C. After rehydration in PBS, 5-m cryostat sections were stained with optimal dilutions of primary antibodies: rat anti -mouse CD4 mAb, and rat anti -mouse CD8 mAb. After washing, sections were serially incubated with optimal dilutions of biotinylated rabbit anti-rat IgG and streptavidine conjugated to horseradish peroxidase ( Dako 
RESULTS
Phenotypic analysis of CD70, CD80, and CD70 / CD80 -transfected B16.F10, B16K1, and TS / A tumor cells Three tumor cell lines with different MHC class I expression status were selected to study and compare the efficiency of CD80 and CD70 in providing protective and curative antitumor immunity. TS /A cells are unable to stimulate a syngeneic antitumor response either in vitro or in vivo in syngeneic mice whereas they express high levels of H -2K d and H -2L d class I MHC molecules ( Fig 1B ) . 33 We did not test D d expression, as previous reports have shown that H -2D d TS /A expression levels are comparable with K d class I expression levels. 34 The B16.F10 subclone used in this study expresses low levels of H -2K b and H -2D b class I MHC molecules in vitro (Fig 1A ) . On the opposite, the B16K1 cells, which are a clone of B16.F10 cells which was transfected with H -2K b genes 31 express high levels of H -2K b (Fig 2D) . TS /A and B16.F10 cells expressed no detectable levels of MHC class II molecules ( data not shown ). The tumor cell lines were stably transfected with the MFG -neo control vector ( -mock ) or with MFG derived vectors encoding either CD70, CD80, or both CD70 and CD80 ( CD70 /CD80 ). Tumor cell lines were selected to express equivalent amounts of CD70 and/ or CD80 ( Fig 2) . CD70 and CD80 expression did not alter the proliferative rate of transfected tumors in vitro nor MHC Ag expression ( data not shown) .
CD70 / CD80 expression in vitro provides a stronger costimulatory signal to induce lymphocyte proliferation or cytokine production than a single costimulatory molecule expression
We first evaluated the biological activity of the transfected costimulatory molecules. For this purpose, we used optimally anti -CD3"± stimulated lymphocytes to test the in vitro ability of CD70 and /or CD80 to costimulate proliferation and cytokine production whatever the MHC status of the tumor cells used. We compared the [ 3 H ]thymidine uptake by activated lymph node cells when cocultured, respectively, with irradiated mock, CD70, CD80, and CD70 /CD80 tumor cells (Fig 3A ) . CD70 and CD80 molecules exhibited different abilities to induce lymphoid cells proliferation. Combination of CD70 and CD80 expression on TS /A and B16.F10 cells was more effective than CD70 or CD80 alone to induce proliferation of lymph node cells ( Fig 3A ) . The ability of the CD70 /CD80 tumor cells to costimulate proliferation of T cells appeared to be mainly supported by CD70 expression as CD80 expression is not sufficient to promote significant proliferation by itself.
We then tested the ability of CD70 and CD80 to costimulate IFN -production when anti -CD3"±activated lymph node cells were stimulated in vitro with irradiated transfected tumor cells. The stimulation of activated lymphoid cells by irradiated CD70 /CD80 B16.F10 cells induced a 2 -to 5-fold increase of the amount of IFN -in supernatants compared with the mock B16.F10 stimulation ( Fig 3B ) . CD80 expression alone by B16.F10 tumor cells did not lead to an increased production of IFN - ( Fig 3B ) with regard to mock B16.F10 cells. In the TS /A model, a low amount of IFN -was detected in culture supernatants ( 1.5 to 4 ng /mL of IFN -). However, no significant difference was noted between the IFN -levels produced by the lymph node cells when stimulated by the different costimulatory molecules expressing TS / A cells ( data not shown) . We have also tested the IL -2 production under the same conditions. The expression of the costimulatory molecule alone or in combination did not improve significantly the synthesis of IL -2 by lymph node cells ( data not shown ).
In these in vitro experiments, expression of both CD70 and CD80 by tumor cells exhibited a strong capacity to 
Incidence of CD70 / CD80 coexpression on tumor growth in vivo
We then tested whether CD80 coexpression with CD70 could cooperate to potentiate an effective and comparable antitumor response in the B16.F10 and TS /A tumor models.
The effects of CD70 and CD80 coexpression on tumor cell growth after injection into syngeneic mice in the two different tumor models are represented in Figure 4 . Mocktumor cells gave rise to rapidly growing tumors with the same tumor growth rate as the parental cells (data not shown) . When TS / A and B16.F10 expressed both CD70 and CD80, a striking inhibition of tumor growth was observed. This inhibition was greater than that obtained when tumor cells expressed only one costimulatory molecule, i.e., CD70 or CD80 ( Fig 4) .
The expression of CD70 or CD80 alone slowed down tumor growth but generally did not lead to the rejection of the transfected tumor (Table 1) . On the contrary, when coexpressed together, CD70 and CD80 significantly decreased tumor incidence. This effect was more pronounced in the TS /A model where 11 of 14 mice injected with TS /A CD70 /CD80 remained tumor-free ( Table 1 ) . In the B16.F10 model, only 6 of 14 C57BL /6 mice remained tumor-free after an s.c. injection of B16.F10 CD70 /CD80. In the B16K1 model, which like TS /A cells express high level of class I molecules, 7 of 10 mice remained tumor-free after an s.c. injection of B16K1 CD70 /CD80 ( Table 1 ) .
The ability of tumor cells expressing costimulatory molecules to elicit a systemic protective immunity against parental cells was then investigated. Mice that remained tumor-free 30 days after the primary injection of the transfected tumor cells were challenged on the opposite flank with 10 5 parental tumor cells. In the TS /A CD70 / CD80 and in the B16K1 CD70 /CD80 tumor group, 5 of 11 mice and 5 of 7 mice, respectively, remained tumor-free after a subsequent challenge with parental tumor cells, whereas in the B16.F10 CD70 /CD80 tumor group no protection against the parental tumor B16.F10 was ever observed (Table 1 ). These findings indicate that the combination of CD70 and CD80 expression on tumor cells has stimulated an effective antitumor response when injected in immunocompetent mice. The induction of a protective immunity against parental tumors was effective only in the highly expressing MHC class I TS /A or B16K1 tumor models.
CD70 / CD80 tumor rejection is T -cell mediated
To evaluate the involvement of T cells in CD70 /CD80 tumor rejection, we tested the growth rate of transfected tumor cells in T-cell immunodeficient mice. The s.c. injection of CD70 / CD80 tumor cells in athymic nude mice gave rise to tumors with the same growth kinetics as mock -transfected cells ( Fig  5A and C ) . These findings demonstrate that T cells are required to induce CD70 /CD80 tumor rejection even in the low MHC class I expressing B16.F10 model. We tried to determine whether CD4 + or CD8 + T cells are implicated in the tumor rejection and the long -lasting immunity. For that we injected 2 -microglobulin ±deficient mice ( MHC class I À / À ) and MHC class II ± deficient mice with CD70 / CD80 -expressing B16.F10 cells. We observed a tumor growth inhibition in MHC class I À / À mice whereas no tumor growth inhibition were observed in MHC class II À / À mice suggesting a potential role in the immune response of the CD4 + T cells (Fig 5B ) . + T cells (RL172 hybridoma) ) . C57BL /6 mice received simultaneously to the tumor cells injections, injections of ascites at days À 2, 0, 3, and 6. When mice were treated with anti CD8 + T cells antibodies we observed a tumor rejection of CD70 /CD80 tumor cells using either TS / A or B16.F10 cells as we observed in immunocompetent wild -type mice. When mice were treated with anti -CD4 + T cells antibodies we did not observe a tumor rejection of CD70 /CD80 tumor cells using either TS / A or B16.F10 cells, confirming a preponderant role of CD4 + T cells in tumor rejection as mentioned in Figure 5B (data not shown) .
Characteristics of T lymphocytes infiltrating the CD70 / CD80 tumors
As T cells are involved in the tumor rejection of the CD70 / CD80 -transfected TS /A and B16.F10 tumors, we analyzed which T-cell populations were preferentially recruited at the tumor site in immunocompetent mice. To study the contribution of each costimulatory molecules in T-cell recruitment, we performed immunochemical studies of CD4 + and CD8 + T cells infiltrating the mock, CD70, CD80, and CD70 / CD80 -transfected tumors (Fig 6) . Transfected B16.F10 and TS /A tumors were excised on days 4, 6, and 12 post -tumor cell injection for the TS /A model and on days 4, 7, and 14 for the B16.F10 model. As shown in Figure 6 , the number of T cells recruited into the tumors expressing costimulatory molecules was significantly higher in the TS /A model than in the B16.F10 model. CD70 /CD80 TS /A as well as CD70 /CD80 B16.F10 tumors showed a late increase in CD4 + T cells and high CD8 + Tcell numbers at the tumor sites. None of the tumors expressing only CD70 or CD80 exhibited the same T-cell A few B cells were present at the tumor site in the B16.F10 and TS /A models, but no significant difference was noted between the different groups (data not shown) .
The combination of CD70 and CD80 expression by engineered tumor cells used as a therapeutic vaccine IL -12 has been reported to activate both MHC -restricted and non ±MHC -restricted antitumor responses. 25, 35 Moreover, IL-12 is known to work in concert with CD80 28,36 ± 38 or, using different pathways, with CD70 in generating antitumor immunity.
17, 39 We then tested whether the CD70 /CD80 -transfected tumor cells could cooperate with IL -12 secreted by transfected fibroblasts in a therapeutic model.
To evaluate the therapeutic ability of tumor cells genetically engineered to express CD70 and CD80 we used low amounts of IL -12. The MC57 and balbc fibroblasts were transfected with cDNA encoding the two subunits of murine IL -12 and selected to produce about 1200 pg of IL-12/ mL / Figure 7 , the low amount of IL-12 secreted by transfected fibroblasts used in this study did not significantly inhibit tumor growth in the B16.F10 tumor model whereas it induced a slight tumor rejection in the TS /A model ( P <.05 ). We then investigated whether CD70 /CD80 coexpression could cooperate with IL -12 to improve the antitumor response. Indeed, injections of irradiated CD70 / CD80 tumor cells to tumor-bearing mice did not significantly reduce the tumor growth rate of parental tumors in comparison with the control group, either in the B16.F10 model ( Fig 7A ) or in the TS /A model (Fig 7B ) . The injections of irradiated IL -12± transfected fibroblasts with irradiated tumor cells expressing CD70 and CD80 produced a significant antitumor response in both tumor models (P < .05 for B16.F10 model and P < .001 for TS /A model ) . Moreover, injection of irradiated IL -12 ±trans-fected fibroblasts plus tumor cells expressing CD70 /CD80 gave a higher rejection of the parental tumor than injection of IL -12 ±transfected fibroblasts alone with a P value of 0.06 for both models. We show here for the first time, that coexpression of CD70 and CD80 by tumor cells with a paracrine secretion of IL-12 could be used as a therapeutic vaccine in both low or high MHC class I expression tumors. + T cells compared with the control groups injected with PBS (Fig 8) . These observations are consistent with an involvement of T cells in the antitumor response observed in vivo.
Immunohistochemical analysis of the treated tumors
DISCUSSION
A major focus in cancer vaccine development has been the generation of Ag -specific T-cell responses. 40 ± 42 The fact that reacting T cells become nonresponsive upon interaction with tumor cells, or at least ignore the tumor cells, could be related to variables. These could include an absence of adhesion molecules, low immunogenicity due either to lack of antigenic peptides and /or reduced MHC expression. This latter phenomenon is widespread in human tumors. 1 ± 6 Defects in MHC class I expression may influence the natural history of the tumor and strongly counteract the potential benefit of T-cell ± based immunotherapy. For these reasons two low immunogenic tumor models, TS /A and B16.F10, were selected. Indeed, the reduced antigenic signal displayed by these two tumors seems to be due to a low expression of tumor associated antigen (TAA ) despite high surface expression of MHC class I molecules in the case of TS /A and a very low expression of MHC class I molecules in the case of B16.F10. The engagement of the TCR by the peptide/ MHC complex is not sufficient by itself to activate naive T cells. Full induction of T-cell responses requires additional costimulatory signals from APC. 4 Most types of tumors, especially of nonhematopoietic origin, do not express T-cell costimulatory molecules, which may lead to nonrecognition by T cell, anergy, or deletion. 43 Depending on the different intrinsic immunogenicities of the transfected tumor cell lines, injection of CD80 -transfected tumors can induce a systemic antitumor immune response in some models. However, CD80 transfection in low immunogenic tumor cells, such as the low MHC class I B16.F10 model used in this study, does not always provide an effective antitumor response in vivo. 15, 16 In this study, we compared the ability of CD70 and CD80 to induce an effective antitumor response in these two different low immunogenic tumors. Nieland et al 23 have previously shown that other costimulatory molecules belonging to the tumor necrosis factor family, like CD40 or CD70, could induce a better immune response than CD80. At the time of T-cell activation, the interaction between CD27 /CD70 (receptor / ligand) supports clonal expansion of the specific T lymphocytes through interlymphocytic interactions by virtue of its ability to relay costimulatory signals for proliferation and cytokine production. 20 ± 22,44 Furthermore, in the case of cancer gene immunotherapy, the CD70 transfection of tumor cells has been demonstrated to increase tumor immunogenicity in several tumor models. 17, 23, 24 As murine CD70 had not been cloned at the time of these experiments, human CD70 as well as human CD80 were used; as in previous studies, it had been shown that human CD70 or CD80 elicited comparable immune responses to murine molecules. 17, 23, 24, 45 We have now shown that CD70 and CD80 costimulatory activities cooperate to improve in vitro anti -CD3"±activated T-cell proliferation in both tumor models (Fig 3A ) . Stimulation of the lymph node cells with an anti -CD3" stimulation enabled us to compare costimulatory proprieties of the transfected B16.F10 and TS /A tumor cells whatever their MHC class I expression levels. The IFN -produced by lymph node cells was increased when B16F10 coexpressed both CD70 and CD80 ( Fig 3B ) . We detected low amounts of IFN -in the culture supernatants of lymph node cells in the TS /A model, but no difference between the stimulatory effects was observed (data not shown) . This could be related to the relative low proliferative rate of the stimulated lymph node cells in the TS /A model compared with the B16.F10 model (Fig 3A ) .
The combination of these two costimulatory molecules had a far greater effect than the expression of a single molecule when it came to an antitumor response in vivo, leading to rejection of the cotransfected cells (Fig 4 and Table 1 ). As we have shown in nude mice, the mechanisms involved in the CD70 /CD80 tumor rejection are T-cell dependent whatever the tumor MHC class I expression ( Fig  5 ) . CD70 and CD80 appeared to cooperate to induce a dual recruitment of both CD8 + and CD4 + T cells in the CD70 / CD80 tumors, which seems linked to the effective antitumor response observed in vivo ( Fig 6) . CD4 + T cells may influence directly, or indirectly via APC, the recruitment and the activation status of CD8 + T cells into the tumor, 46 by producing IFN -, up -regulating MHC class I, and allowing CTL recognition of the targets as has already been described for the B16.F10 model. As the kinetics of CD8 + T cells recruitment into the CD70 /CD80 tumors were correlated with the in vivo regression of the CD70 /CD80 tumor volumes ( between day 6 and day 12 ) ( Fig 6) , we are further evaluating the generation of cytolytic CD8 + T cells in mice that rejected the CD70 /CD80 tumors. After two in vitro restimulations with the CD70 / CD80 -transfected cells, a low but specific lytic activity of CD8 + T cells against parental TS /A cells in the TS /A model has been detected (data not shown ). No lytic activity was observed against the parental MHC class I low B16.F10 cells. The lack of protective immunity in the B16.F10 model could be related firstly to the inefficiency of the CTL primed by the CD70 /CD80 -transfected cells to recognize and kill the parental MHC class I low cells. This failure could also be related to the low overall number of infiltrating T cells and to the lack of an early CD8 + T-cell recruitment in the CD70 /CD80 B16.F10 tumor compared with the CD70 / CD80 TS / A tumors ( Fig 6 ) .
Enhancing the CTL activity of the CD70 / CD80 -primed T cells would allow us to induce a therapeutic activity with the transfected cells. In fact, we have observed that when B16.F10 cells were treated with IFN -( 100 international units/ mL for 48 hours ) to induce high MHC class I expression, they became more sensitive to CTL -mediated lysis (data not shown) .
We decided to coinject a combination of transfected CD70 /CD80 tumor cells with IL -12± producing syngeneic fibroblasts in tumor-bearing mice. Indeed IL -12 has already been shown to activate both specific Th -1 responses and non ± MHC -restricted NK antitumor response. 25, 35 Antitumor activity of IL-12 is thought to be mediated mainly by in vivo induction of IFN. 28 Moreover, IL -12 is also known to cooperate with CD70 or CD80 pathways to augment antitumor response 17, 28, 36, 39, 47 or to increase the generation of cytolytic effectors. 48 ± 52 The injections of irradiated mIL -12 ± transfected fibroblasts combined with irradiated tumor cells expressing CD70 and CD80 costimulatory molecules provided an antitumor response whereas both transfected tumor cells alone and, in these experimental conditions, IL-12 ±transfected fibroblasts alone, were ineffective ( Fig 7 ) .
The present study identified two molecules, CD70 and CD80, whose expression by low immunogenic tumor cells increased their immunogenicities irrespective of the MHC class I expression. When CD70 and CD80 are cotransfected into MHC class I positive TS /A tumor cells or B16K1 tumor cells, those cells are then able to induce tumor-specific CTL and memory responses. This was not observed in MHC class I low B16.F10 where a long -lasting immunity could not be elicited. The design of efficient cancer vaccines based on the enhancement of tumor costimulation should therefore take into account the MHC status expression of the tumor. The lack of MHC class I molecules could be counteracted by combining different costimulatory molecules with cytokines known to cooperate in the immune antitumor response. Regardless of the mechanisms involved, CD70 and CD80 exemplify a combination of molecules that can tip the balance between T-cell ±mediated immunity and tumor growth onto the side of the T cells.
